ArticleBMC gastroenterology2025
Elevated CircYthdc2 expression is correlated with aggressive features and poor progression-free survival in hepatocellular carcinoma.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The mCells · 2026Review
- Exosomal circRNAs in hepatocellular carcinoma: Implications for the development and therapeutic resistance of hepatocellular carcinoma (Review).International journal of oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveLiver hepatocellular carcinoma (LIHC) is a major contributor to cancer-related mortality. While early detection is crucial for improving outcomes, current diagnostic methods lack optimal sensitivity and specificity. Circular RNAs (circRNAs) have emerged as promising biomarkers due to their stability and tissue-specific expression.
methodsBioinformatic analysis was performed using UALCAN database to examine YTHDC2 methylation and expression patterns. Tissue and serum samples were collected from 72 LIHC patients and matched controls. CircYTHDC2 expression was assessed in tissues, serum, and cell lines via qRT-PCR. CircYTHDC2's diagnostic potential was evaluated through ROC analysis and stability testing. Associations between circYTHDC2 levels, clinicopathological features, and survival were analyzed.
resultsBioinformatic analysis revealed reduced YTHDC2 promoter methylation and elevated expression in LIHC tissues. CircYTHDC2 showed significant upregulation in LIHC tissues, serum, and cell lines compared to controls. ROC analysis demonstrated high diagnostic accuracy for circYTHDC2 in tissues (AUC = 0.846) and serum (AUC = 0.788). CircYTHDC2 exhibited remarkable stability against RNase degradation. Elevated circYTHDC2 levels significantly correlated with advanced BCLC stage, larger tumor size, intrahepatic metastasis, and portal invasion. High circYTHDC2 expression was associated with shorter progression-free survival (P = 0.025). Additionally, we found circYTHDC2 bound to YTHDC2 and was positively regulated by YTHDC2 in an m6A-dependent manner.
conclusionCircYTHDC2 represents a stable, clinically viable biomarker for LIHC, demonstrating significant diagnostic accuracy and prognostic value. Its strong correlation with aggressive tumor features and survival outcomes suggests potential utility in clinical management of LIHC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.